Engineers Gate Manager LP Otonomy, Inc. Transaction History

Engineers Gate Manager LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.25 - $2.24 $4,517 - $40,476	-18,070 Reduced 55.03%	14,764 $4,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $2.51 $6,394 - $9,332	-3,718 Reduced 10.17%	32,834 $68,000
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $1,391 - $1,998	809 Added 2.26%	36,552 $88,000
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $12,247 - $16,740	-7,247 Reduced 16.86%	35,743 $74,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $4,897 - $8,830	-4,014 Reduced 8.54%	42,990 $83,000
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.67 $74,116 - $96,063	-35,979 Reduced 43.36%	47,004 $105,000
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $56,037 - $140,206	22,505 Added 37.21%	82,983 $212,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $210,463 - $391,292	60,478 New	60,478 $391,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.